-
1 Comment
Aerie Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 0.6% below its 200 day moving average.
From a valuation standpoint, the stock is 99.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.9.
Aerie Pharmaceuticals, Inc's total revenue rose by 0.1% to $25M since the same quarter in the previous year.
Its net income has increased by 16.2% to $-46M since the same quarter in the previous year.
Finally, its free cash flow grew by 174.6% to $22M since the same quarter in the previous year.
Based on the above factors, Aerie Pharmaceuticals, Inc gets an overall score of 4/5.
| Exchange | F |
|---|---|
| ISIN | US36317J2096 |
| Sector | None |
| Industry | None |
| CurrencyCode | EUR |
| Beta | nan |
|---|---|
| Dividend Yield | 0.0% |
| Market Cap | 730M |
| PE Ratio | None |
| Target Price | 25.45 |
None
Here's how to backtest a trading strategy or backtest a portfolio for 0P0.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
